A Phase 1, Double-blind, Placebo-Controlled, Single Oral Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTI-2088 Tablet in Healthy Adult Subjects

Trial Profile

A Phase 1, Double-blind, Placebo-Controlled, Single Oral Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTI-2088 Tablet in Healthy Adult Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs HTI-2088 (Primary)
  • Indications Diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Hengrui Therapeutics
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017.
    • 08 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.
    • 05 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top